Technology of Myelopidum
Development of Technology of Production of Immunomodulating Pharmaceutical Myelopidum
Tech Area / Field
- MED-DRG/Drug Discovery/Medicine
- BIO-IND/Industrial Biotechnology/Biotechnology
3 Approved without Funding
Institute of Immunology, Russia, Moscow
- NPC "Medical Immunology", Russia, Moscow
Project summaryThe aim of the Project is a performance of the research and design works in order to create a technology of production of Myelopidum having been developed as a pharmaceutical remedy for defense of human immune system against the weapons of mass destruction.
Myelopidum consists of the complex of low molecular these peptides of natural origin. The preparation passed successfully clinical trials, was registered and approved by the Ministry of Health of Russian Federation and permitted to be used in clinical practice for adults and children.
Along with usage to restore immune system after weapons of mass destruction Myelopidum is an effective remedy for correction of immunodeficiencies caused by unfavorable ecological factors. Its use in frequently sick persons patients living in the areas with high concentration of chemical industry, metallurgy and mining allow to decrease the number of chronic infectious diseases typical for inpiduals living on the given territories. The preparation is also used in surgical and gynecological practice to treat septic and purulent processes, chronic and long-lasting bacterial and viral infections, in complex therapy of purulent-septic conditions and sepsis in children and adults. The capacity of Myelopidum to restore functional activity of immune cells allows using it for the complex treatment of patients with acute leukemia and also for prevention of development of oncological diseases in the inpiduals after radiation disasters.
The Project will result in the development of a new technology of production of a new pharmaceutical based on endogenous peptides and destined for immune system restoration.
According to the data of health service of Russia approx. 30% of population residing on ecologically unfavorable industrial areas need an immunocorrection. Basing on the data on disease spreading at immunodeficiencies in CIS countries we can foresee an increase of Myelopidum need up to 2.0 - 2.5 million therapeutic doses a year.
Potential Role of Foreign Collaborators
Development of industrial technology of the pharmaceutical manufacture and joint production and realization on the territory of Russia and CIS countries. Other types of joint activity in the Project framework and after its completing are appreciated and to be discussed.